Pre-clinical studies on murine models of breast cancer have documented that, anti-FGB treatment, when combined with anti-PDL-1 immunotherapy, led to reduced polarization of macrophages to TAMs, increased infiltration of CD8+ cytotoxic T lymphocytes, and significant reduction of tumor volume and lung metastases (44). Here, CD8A is linked to breast cancer.